Compositions and methods for treating lung injury
The present invention provides methods of reducing lung injury in a subject in need thereof, comprising administering to the subject an effective amount of an agent that inhibits the activity of SUR1.
1 . A method of treating acute lung injury in a human subject in need thereof, comprising administering to the subject an effective amount of an agent that inhibits the activity of SUR1, wherein the agent is glibenclamide, wherein glibenclamide is administered to the subject in an amount of between about 0.5 mg/day to about 10 mg/day, wherein the subject is on a mechanical ventilator.
2 . The method of claim 1 , wherein the lung injury is associated with acute respiratory distress syndrome (ARDS).
3 . The method of claim 1 , wherein the lung injury is ventilator induced lung injury (VILI).
4 . The method of claim 1 , wherein the subject has coronavirus infection.
5 . The method of claim 1 , wherein the subject is infected with a pathogen.
6 . The method of claim 1 , wherein SUR1 is contained in a complex.
7 . The method of claim 1 , wherein the SUR1 containing complex comprises a SUR1-TRPM4 channel.
8 . The method of claim 1 , wherein the SUR1 containing complex comprises SUR1 and MRP8/14.
9 . The method of claim 1 , wherein the agent that inhibits the activity of SUR1 is administered as a bolus injection, an infusion, or as a bolus injection in combination with an infusion.
10 . The method of claim 1 , wherein the agent that inhibits the activity of SUR1 is administered as a loading dose followed by a constant infusion.